Haploidentical hematopoietic stem-cell transplantation for acute myeloid leukemia in first relapse after complete remission by standard induction chemotherapy
10.3760/cma.j.issn.0254-1785.2011.03.004
- VernacularTitle:HLA半相合造血干细胞移植治疗首次复发的急性髓系白血病
- Author:
Kunyuan GUO
;
Zhaoyang SONG
;
Bingyi WU
;
Yuhua LI
;
Lan DENG
;
Yi SU
;
Jian CHEN
;
Wenbin SAO
;
Yi SUN
;
Sanbin WANG
;
Da LI
;
Yuanbin WU
;
Yongzhen HU
;
Quanyi LU
- Publication Type:Journal Article
- Keywords:
Leukemia,myeloid,acute;
Recurrence;
Hematopoietic stem cell transplantation;
HLA antigens
- From:
Chinese Journal of Organ Transplantation
2011;32(3):141-143
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the therapeutic effects of haploidentical hematopoietic stem-cell transplantation (Haplo-PBSCT) for acute myeloid leukemia in first relapse after complete remission by standard induction chemotherapy. Methods Eighty-nine cases of AML in first relapse after complete remission by standard DA/Hi-Ara-C regimens induction chemotherapy were evaluated retrospectively. Fiftythree cases were grafted by haplo-PBSCT and 26 cases were treated with iDA/Mid-Ara-C or MA/ Mid- Ara-C agents. Results The second remission rate in haplo-PBSCT group and continuous chemotherapy group was 86. 7 % (46/53 cases) and 38. 1% (9/23 cases) respectively (P＜0. 01). Survival postprogression (SPP) at 36th month was 43. 4 % (23/53 cases) in haplo-PBSCT group and 11.5 % (3/26 cases) in continuous chemotherapy group (P ＜ 0. 05). Conclusion Haplo-PBSCT could significantly increase the second remission rate and prolong the survival time of patients with acute myeloid leukernia in first relapse after complete remission by standard induction chemotherapy.
